Bristol-Myers Squibb: Schizophrenia trials

The registry lists 22 Schizophrenia studies with Bristol-Myers Squibb as lead sponsor. 8 are open to participants now and 10 have results posted.

Phase 1 2Phase 2 1Phase 3 13Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingNCT07686263Phase 3
• A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingNCT07424404Phase 3
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)RecruitingNCT07379827
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingNCT07288567Phase 3
• A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingNCT07221877Phase 4
• Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)RecruitingNCT07101094
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTRecruitingNCT07061288Phase 1
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaRecruitingNCT06882785Phase 3
• Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaCompletedNCT06572449Phase 3Results posted
• A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaCompletedNCT05919823Phase 3Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaTerminatedNCT05643170Phase 3Results posted
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05145413Phase 3Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)CompletedNCT04820309Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)CompletedNCT04738123Phase 3Results posted
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)CompletedNCT04659174Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)CompletedNCT04659161Phase 3Results posted
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaCompletedNCT03697252Phase 2Results posted
• A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic SyndromeTerminatedNCT00508157Phase 4Results posted
• Long-Term Real-World Safety of Cobenfy in Adults With SchizophreniaActive, not recruitingNCT07783373
• Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT UsersCompletedNCT07571148
• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05304767Phase 3
• Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedNCT02831231Phase 1